3 July 2019 in Journal of Natural Medicines
The crude drug Sojutsu, as defined by the Japanese Pharmacopoeia, is the rhizome of Atractylodes lancea De Candolle, Atractylodes chinensis Koidzumi, or their interspecific hybrids (Asteraceae). Sojutsu is one of the traditional Kampo formulas, which are administered to patients suffering from stomach disorders, edema, and nephrotic syndrome. Although antiinflammatory effects of Sojutsu have been reported, its effects on the liver and kidney have not been extensively investigated. Here, we used a Sojutsu sample identified as A. chinensis rhizome and isolated several constituents from its ethyl acetate (EtOAc)-soluble fraction that decreased production of the proinflammatory mediator nitric oxide (NO) in interleukin 1β-treated rat hepatocytes. Among the constituents in this fraction, atractylodin showed the highest activity to suppress NO production, whereas hinesol, β-eudesmol, and α-bisabolol showed low activity. Atractylodin decreased the levels of inducible nitric oxide synthase, tumor necrosis factor α, and lipocalin 2 messenger RNAs (mRNAs). The EtOAc-soluble fraction of the A. chinensis rhizome extract was administered daily for 20 weeks to high immunoglobulin A (HIGA) mice, whose pathological findings resemble human immunoglobulin A nephropathy. This fraction decreased the weight of white adipose tissue and decreased mesangial proliferation and immunoglobulin A deposition in glomeruli. These results indicate that the EtOAc-soluble fraction, which included antiinflammatory constituents, may be responsible for improvement of the mesangial lesions in HIGA mice.
17 December 2019 in Phytotherapy Research
22 November 2018 in Journal of Natural Medicines
13 November 2019 in Journal of Natural Medicines
31 January 2020 in Functional Foods in Health and Disease
Background: The fruit of bitter melon (Momordica charantia L.) has traditionally been used as a crude drug to treat obesity and diabetes mellitus. Previously, we reported that an ethyl acetate (EtOAc)-soluble fraction of bitter melon fruit extract showed anti-inflammatory effects on interleukin-1β-treated rat hepatocytes. The liver plays a pivotal role to maintain homeostasis of glucose and lipid. It is speculated that the administration of an EtOAc-soluble fraction of a bitter melon fruit extract (BMFA) may change the expression profile of hepatic genes involved in inflammation, glucose metabolism, and lipid metabolism. Objective: We aimed to evaluate the effects of BMFA on the gene expression in the liver of ob/ob mice, which are deficient in leptin and are used as a diabetes mellitus model. The changes may be related to hepatic steatosis and obesity. Methods: Male 8-week-old ob/ob mice (average body weight, 40.9 g) were fed a standard diet with and without BMFA (ob/ob+BMFA and ob/ob–BMFA groups, respectively; 4 mice/group) for seven days. The livers were excised to prepare total RNA for microarray expression analyses. Signal ratios (i.e., ob/ob+BMFA versus ob/ob–BMFA group) were calculated to compare gene expression. Results: The mRNA levels of 2,632 genes were significantly changed in the livers of ob/ob+BMFA mice when compared with those of ob/ob–BMFA mice. As expected, proinflammatory cytokine and chemokine genes were significantly downregulated by BMFA. The acyl-Coenzyme A thioesterase 3 gene in fatty acid oxidation was upregulated in ob/ob+BMFA liver, whereas free fatty acid receptor 2 and solute carrier family 27 member 3 genes were downregulated. Most genes involved in glycolysis and gluconeogenesis were not affected by BMFA. In contrast, the level of peroxisome proliferator-activated receptor γ coactivator 1α mRNA significantly increased in ob/ob+BMFA mice, suggesting that BMFA administration may reduce insulin resistance in ob/ob mice. Conclusion: Our study suggested that BMFA may possess anti-inflammatory effects and enhance fatty acid metabolism in ob/ob mouse liver. These data imply the possibility that EtOAc-soluble constituents in bitter melon fruit may improve lipid accumulation in the liver during obesity and diabetes mellitus, as well as non-alcoholic fatty liver disease. Keywords: Momordica charantia, gene expression, inflammation, diabetes mellitus, non-alcoholic fatty liver disease.